On Thursday, Following Stocks were among the “Top 100 Losers” In U.S. Stock Exchange: National Bank of Greece (ADR) (NYSE:NBG), Keryx Biopharmaceuticals (NASDAQ:KERX), Sonus Networks, Inc (NASDAQ:SONS), Coach Inc (NYSE:COH)
National Bank of Greece (ADR) (NYSE:NBG)’s shares dwindled -3.68%, and closed at $1.31. The stock has the beta value of 2.49, and its volatility for the week is 8.21%, while for the month it is 6.17%. The company has the market capitalization of $4.38B. The company holds the book value per share of 3.50, whereas cash per share is 4.13. Price to book ratio remained 0.37, while price to sale ratio is 0.82. Analysts mean recommendation for the stock is said to be 3.00 (where 1=Buy, 5=sale).
National Bank of Greece S.A., together with its subsidiaries, offers diversified financial services primarily in Greece. The company is involved in retail and commercial banking, investment administration, investment banking, insurance, investment activities, and securities trading activities. It offers demand deposits, savings deposits, and time deposits, and current accounts; investment products; consumer loans, personal loans, mortgage loans, automobile loans, overdraft facilities, and foreign currency loans, in addition to letters of credit and guarantees; credit cards; currency swaps and options; and ATMs. The company also provides financial and investment advisory services, foreign exchange, custody services, and trade finance services; and shipping finance, project finance, leasing, factoring, treasury, private banking, private equity, and brokerage services, in addition to asset administration, counting mutual funds and closed end funds.
Keryx Biopharmaceuticals (NASDAQ:KERX), declined -3.62%, and closed at $12.78. The company has the market capitalization of $2.70M. The beta value of the stock is 3.13. On the other hand the stock’s volatility for the week is 5.28%, and for the month is 4.79%. The stock’s price to book ratio is 15.97, however price to sale ratio is 122.59. Analyst’s mean recommendation regarding this stock is 1.80. (where 1=Buy, 5=Sale).
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, in addition to treats iron deficiency anemia. Auryxia is also used to control serum phosphorus levels in patients with chronic kidney disease on dialysis. The company also has sublicense agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan. It also has planned alliance with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in New York, New York.
Sonus Networks, Inc (NASDAQ:SONS), dipped -3.58%, and closed at $8.08, hitting new 52-week low of $8.03. The stock has price to sale ratio of 1.35, however, price to book ratio is 1.66. With recent decline, the year-to-date (YTD) performance reflected a -59.29% decline above last year. During the past month the stock lose -53.00%, bringing three-month performance to -59.09% and six-month performance to -56.32%. The mean recommendation of analysts for this stock is 1.50. (where 1=Buy, 5=Sale).
Sonus Networks, Inc. provides networked solutions for communications service providers and enterprises. Its products comprise session border controllers (SBC) that address the network requirements for small, medium, and large businesses, in addition to for communications service providers; and open services switches for converting various types of voice signals into Internet protocol (IP) packets and transmitting those IP packets over a data network.
Coach Inc (NYSE:COH), dropped -3.58%, and closed at $40.69. The stock volatility for the week is 1.99%, while for the month remained 1.81%. The company holds consensus target price of $39.86.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed 2.05 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -22.70% and Annual EPS growth for the past 5 years is considered as 7.90%.
The mean recommendation of analysts for this stock is 2.90. (where 1=Buy, 5=Sale).
Coach, Inc. provides luxury accessories and lifestyle collections for women and men in the United States and internationally. It offers handbags, money pieces, wristlets, rings, charms, and cosmetic cases for women; and business cases, computer bags, messenger-style bags, totes, wallets, card cases, and belts, in addition to time administration and electronic accessories for men. The company also provides wearables, such as outerwears, gloves, scarves, and hats; jewelry comprising bracelets, necklaces, rings, and earrings made with sterling silver, leather, and non-precious metals; travel bags, counting luggage, travel kits, and valet trays; fragrances comprising eau de perfume spray, eau de toilette spray, purse spray, and body lotion for women; and fragrances for men, in addition to footwear, watches, and sunglasses.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
